ReShape Lifesciences™ Featured in BioTuesdays
“We have all the ingredients in place to deliver safe, effective and sustainable therapies that address a growing global health crisis associated with increased prevalence of obesity, associated COVID-19 risk factors and metabolic diseases, including diabetes, cancer and hypertension,” stated
ReShape Lifesciences’ lead product, Lap-Band®, with over 1,000,000 placements worldwide, provides minimally invasive, long-term treatment of obesity and is an alternative to more aggressive surgical stomach-stapling weight loss procedures.
Created over a decade ago, BioTuesdays covers small and medium sized healthcare companies to provide invaluable exposure for innovative technologies and compelling investment stories within the industry.
The full article can be viewed online here.
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the
Forward-Looking Safe Harbor Statement:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties are described more fully in the Company's filings with the
ReShape Lifesciences Investor Contact:
Chief Financial Officer
Assistant Vice President
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e4158e06-4be6-42d3-9ace-9a989551d7ca
Source: ReShape Lifesciences Inc